DOCSLIB.ORG

The Effect of Certolizumab Drug Concentration and Anti-Drug Antibodies on TNF Neutralisation L.C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Certolizumab Drug Concentration and Anti-Drug Antibodies on TNF Neutralisation L.C The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation L.C. Berkhout1, E.H. Vogelzang2, M.H. Hart1, F.C. Loeff1, L. Dijk1, N.I.L. Derksen1, R. Wieringa3, W.A van Leeuwen3, C.L.M. Krieckaert2, A. de Vries3, M.T. Nurmohamed2,4, G.J. Wolbink1,2, T. Rispens1 1Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam UMC, Academic Medical Centre, University of Amsterdam, The Netherlands; 2Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, The Netherlands; 3Biologics Lab, Sanquin Diagnostic Services, Amsterdam, The Netherlands; 4Amsterdam Rheumatology and immunology Center | Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. Abstract Objective Tumour necrosis factor (TNF) inhibitors like certolizumab, elicit an immunogenic response leading to the formation of anti-drug antibodies (ADAs). We sought to mechanistically investigate the relationship between certolizumab concentrations, ADAs, and the effective TNF neutralising capacity in sera of rheumatoid arthritis (RA) patients. TNF neutralising capacity of certolizumab was compared to the neutralising capacity of adalimumab. Methods Serum samples were collected from 40 consecutive certolizumab-treated RA patients at baseline and 4, 16, 28 and 52 weeks after treatment initiation [Dutch Trial Register NTR (Nederlands Trial Register) Trial NL2824 no. 2965]. Certolizumab concentration and ADA titre were measured with a certolizumab bridging enzyme-linked immunosorbent assay (ELISA) and a drug-tolerant radioimmunoassay (RIA), respectively. TNF neutralisation by certolizumab and adalimumab, in presence or absence of ADAs, was analysed with the TNF-sensitive WEHI bioassay. Results Despite a high incidence of ADAs during one year of follow-up (65%; 26/40 patients), certolizumab levels of >10 μg/ml were measured in most patients. The capacity for TNF neutralisation highly correlated with certolizumab serum concentration, whereas no association with ADAs was observed. Similar results were obtained for adalimumab. The relative in vitro neutralising potency was higher for certolizumab compared to adalimumab. Conclusion Anti-certolizumab antibodies were detected in a large proportion of patients, but in most cases where ADAs were detected, certolizumab was also present in high concentrations, directly correlating with in vitro neutralising capacity. These results indicate that measurement of certolizumab drug levels, rather than ADAs, have direct clinical signifcance. Key words certolizumab, anti-drug antibodies, TNF, rheumatoid arthritis, adalimumab Clinical and Experimental Rheumatology 2020; 38:Clinical 306-313. and Experimental Rheumatology 2020 TNF neutralisation by certolizumab / L.C. Berkhout et al. Lea C. Berkhout, Msc Introduction viously, we have shown that the anti- Erik H. Vogelzang, MD, LLM Biological disease-modifying anti- body response to a range of therapeutic Margreet H. Hart, Bsc rheumatic drugs (bDMARDs) have antibodies, including certolizumab and Floris C. Loeff, Msc been developed to inhibit the activity of adalimumab, is highly restricted to Lisanne Dijk, Msc Ninotska I.L. Derksen, Msc infammatory cytokines such as tumour the antigen binding site, thereby pre- Roeland Wieringa, PhD necrosis factor (TNF). These TNF in- dominantly neutralising (13, 14). In a W. Astrid van Leeuwen hibitors have proven to be a successful number of studies, increasing serum Charlotte L.M. Krieckaert, MD, PhD treatment option for patients with rheu- concentrations of TNF inhibitors, in- Annick de Vries, PhD matoid arthritis (RA) and other infam- cluding certolizumab, were associated Michael T. Nurmohamed, MD, Prof. matory disorders (1, 2). Therapeutic with better clinical outcome (4, 7, 15- Gerrit J. Wolbink, MD, PhD antibodies such as certolizumab have 18). Furthermore, the amount of TNF Theo Rispens, PhD been shown to elicit an immunogenic inhibition will depend on the strength Please address correspondence to: response leading to the formation of of binding between TNF inhibitor and Theo Rispens, Department of Immunopathology, anti-drug antibodies (ADAs). How- ADAs on the one hand and TNF inhibi- Sanquin Research, ever, the reported incidence, and levels tor and TNF on the other hand. In other Plesmanlaan 125, of anti-certolizumab antibodies varies words, the balance between TNF inhib- 1066 CX, Amsterdam, The Netherlands. highly between different studies (~5- itor concentration, ADA titre and TNF E-mail: [email protected] 37% of the patients) (2-4). In a recent concentration plays a role in determin- Received on February 19, 2019; accepted study by Jani et al. detection of ADAs ing the TNF neutralising effcacy of the in revised form on May 29, 2019. in certolizumab-treated RA patients TNF inhibitor. © Copyright CLINICAL AND was not associated with the 12 months In the present study we describe the in- EXPERIMENTAL RHEUMATOLOGY 2020. European League Against Rheumatism cidence of anti-certolizumab antibod- (EULAR) response (4). In contrast, in ies, as well as the relationship between certolizumab-treated Crohn’s disease serum certolizumab concentrations and patients persistent ADAs were corre- the TNF neutralising capacity in pres- lated with reduced effcacy, while tran- ence and absence of ADAs. We com- sient ADAs were not (5). These mixed pared the certolizumab neutralising results are seemingly in contrast with capacity with the neutralising capacity many studies demonstrating clear cor- of adalimumab, since these drugs are relations between ADA formation to structurally different and have a differ- adalimumab or infiximab and a lower ent binding strength for TNF (19). likelihood of minimal disease activity or clinical remission (6-10). Materials and methods Reprints will not be available from the The detection of ADAs in patients var- Details about the methodology can be author. ies widely between studies, depending found in the Supplementary fle. Brief- Funding: this work was supported by on duration of follow-up, concomitant ly, certolizumab concentration and ZonMw, the Netherlands Organisation for medication, the type of TNF inhibi- anti-certolizumab antibody titre were Health Research and Development, in the tor and the type of assay that is used measured with a rabbit anti-certolizum- program 2Treat (grant no. 436001001). The certolizumab and adalimumab cohort to detect ADAs; a golden standard for ab bridging ELISA and a one-tiered or studies were partially supported by UCB the quantifcation of ADAs is missing two-tiered certolizumab RIA, respec- (IIS-2014-101540) and AbbVie (11). In particular, drug concentration tively, in 40 consecutive RA patients (ACA-NETH-05-012), respectively. may profoundly affect the detection of starting certolizumab treatment [Dutch UCB and AbbVie had no involvement in ADAs, depending on how drug-tolerant Trial Register NTR (Nederlands Trial the study design; in the collection, analysis, the ADA assay is. Importantly, ADAs Register) Trial NL2824 no. 2965]. The and interpretation of data. and drug levels will affect each other study was approved by the medical eth- Competing interests: mutually. ics committee of the Slotervaart Hospi- M.T. Nurmohamed has received consultancy ADAs are generally expected to only tal and Reade Medical Research Ethics fees from Abbott,Roche, Pfzer, MSD, UCB, SOBI and BMS, and payment for lectures affect treatment effcacy by lower- Committee, Amsterdam, the Nether- from Abbott, Roche and Pfzer. ing exposure to free active drug, via lands (CCMO NL35209.048.11). All G.J. Wolbink has received a research neutralisation and/or enhanced clear- patients gave written informed consent. grant from Pfzer (paid to the institution) ance. Hence, ADAs might only infu- To determine the TNF neutralising ac- and honoraria for lectures from UCB, ence clinical response when they affect tivity of certolizumab in patient sera, Pfzer, AbbVie, Biogen and BMS. pharmacokinetics (PK) to a noticeable in presence or absence of ADAs, the T. Rispens has received honoraria for degree (12). When enough free active TNF-sensitive WEHI bioassay was lectures from Pfzer, AbbVie and Regeneron, and a research grant from Genmab. drug is left to bind to its target, despite used. The TNF neutralising capacity of The other co-authors have declared no the presence of ADAs, ADAs are un- certolizumab was compared with the competing interests. likely to impair clinical response. Pre- neutralising capacity of adalimumab. A Clinical and Experimental Rheumatology 2020 307 TNF neutralisation by certolizumab / L.C. Berkhout et al. Fig. 1. Development of bridging ELISA for certolizumab. A cross-linking assay in which for both capture and detection polyclonal rabbit anti-idiotype antibodies were used, resulted in a sensitive assay to quantify certolizumab serum concentrations. A: Schematic overview of the certolizumab concentration assay. Certolizumab in serum is captured by polyclonal rabbit-anti certolizumab antibodies. Subsequently, biotinylated F(ab’)2 fragments of the same polyclonal rabbit anti-certolizumab antibodies are added for detection of certolizumab. B: Representative calibration curve of the certolizumab concentration assay. C: Inhibition of certolizumab specifc signal by increasing concentration of TNF. The concentration assay does not detect certolizumab bound to its target, assuring that only functional certolizumab is measured in this assay. Table I. Demographics, previous and con- tres (20–830 AU/ml anti-certolizumab antibodies
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Xolair/Omalizumab
    Therapeutic/Humanized Antibodies ELISA Kits ‘Humanized antibodies” are ‘Animal Antibodies’ that have been modified by recombinant DNA-technology to reduce the overall content of the animal- portion of immunoglobulin so as to increase acceptance by humans or minimize ‘rejection’. By analogy, if the hands of a mouse is actually responsible for grabbing things then ‘humanized-mouse’ will only contain the ‘mouse hands’ and the rest of the body will be human. Since the size of the IgGs is similar in mouse and human, the size of the native mouse IgG and the ‘humanized IgG’ does not significantly change. Antigen recognition property of an antibody actually resides in small portion of the IgG molecule called the ‘antigen binding site or Fab’. Therefore, humanized antibodies contain the minimal portion from the Fab or the epitopes necessary for antigen binding. The process of "humanization of antibodies" is usually applied to animal (mouse) derived monoclonal antibodies for therapeutic use in humans (for example, antibodies developed as anti-cancer drugs). Xolair (Anti-IgE) is an example of humanized IgG. The portion of the mouse IgG that remains in the ‘humanized IgG’ may be recognized as foreign by humans and may result into the generation of “Human Anti-Drug Antibodies (HADA). The presence of anti-Drug antibody (e.g., Human Anti-Rituximab IgG) that may limit the long-term usage the humanized antibody (Rituximab). Not all monoclonal antibodies designed for human therapeutic use need be humanized since many therapies are short-term. The International Nonproprietary Names of humanized antibodies end in “-zumab”, as in “omalizumab”. Humanized antibodies are distinct from chimeric or fusion antibodies.
    [Show full text]
  • Anti-TNF Treatment in Inflammatory Bowel Disease
    xx xx 48 ANNALSJanuary OF GASTROENTEROLOGY 20, 2007, KIFISIA, A THENS2007, 20(1):48-53x, G xxREECE x Lecture Anti-TNF Treatment in Inflammatory Bowel Disease Suna Yapali, Hulya over Hamzaoglu INTRODUCTION disease than ulcerative colitis.2 Moreover, enhanced secre- tion of TNF-alpha from lamina propria mononuclear cells Crohn’s disease and ulcerative colitis are chronic in- has been found in the intestinal mucosa of IBD patients.3 flammatory disorders of the gastrointestinal tract. Although In Crohn’s disease tissues, TNF-alpha positive cells have the primary etiological defect stil remains unknown, in the been found deeper in the lamina propria and in the submu- last decade impotant progress has been made concerning cosa, whereas TNF-alpha immunoreactivity in ulcerative the immunological basis of the disease. Genetic, environ- colitis is, mostly, located in subepithelial macrophages.4 mental and microbial factors result in repeated activation There may be insufficient increased release of soluble TNF of mucosal immune response. Tumor necrosis factor alpha receptor from lamina propria mononuclear cells of patients (TNF-alpha) is one of the central cytokines in the under- with IBD in response to enhanced secretion of TNF-alpha.5 lying pathogenesis of mucosal inflammation in inflamma- TNF-alpha in the stool have also been found from children tory bowel disease (IBD) and has been the primary target with active IBD,6 and elevated levels of TNF-alpha have of biologic therapies. been found increased in the serum of children with active 7 Role of TNF-alpha in pathogenesis of ulcerative colitis and Crohn’s colitis. inflammatory bowel disease Anti-TNF antibodies and fusion proteins: TNF-alpha is produced by activated macrophages and We certainly have many ways to block TNF-alpha.
    [Show full text]
  • The Change of Fingolimod Patient Profiles Over Time
    Journal of Personalized Medicine Article The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0 Tjalf Ziemssen 1,* and Ulf Schulze-Topphoff 2 1 Zentrum für Klinische Neurowissenschaften, Universitätsklinikum Carl Gustav Carus, D-01307 Dresden, Germany 2 Novartis Pharma GmbH, D-90429 Nuremberg, Germany; [email protected] * Correspondence: [email protected] Abstract: (1) Background: Fingolimod (Gilenya®) was the first oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Since its approval, the treatment landscape has changed enormously. (2) Methods: Data of PANGAEA and PANGAEA 2.0, two German real-world studies, were descriptively analysed for possible evolution of patient profiles and treatment behavior. Both are prospective, multi-center, non-interventional, long-term studies on fingolimod use in RRMS in real life. Data of 4229 PANGAEA patients (recruited 2011–2013) and 2441 PANGAEA 2.0 patients (recruited 2015–2018) were available. Baseline data included demographics, RRMS characteristics and disease severity. (3) Results: The mean age of PANGAEA and PANGAEA 2.0 patients was similar (38.8 vs. 39.2 years). Patients in PANGAEA 2.0 had shorter disease duration (7.1 vs. 8.2 years) and fewer relapses in the year before baseline (1.2 vs. 1.6). Disease severity at baseline estimated by Citation: Ziemssen, T.; EDSS and SDMT was lower in PANGAEA 2.0 patients compared to PANGAEA (EDSS difference Schulze-Topphoff, U. The Change of 1.0 points; SDMT difference 3.3 points). (4) Conclusions: The results hint at an influence of changes in Fingolimod Patient Profiles over the treatment guidelines and the label on fingolimod patients profiles over time.
    [Show full text]
  • Infliximab, Adalimumab and Golimumab for Treating Moderately
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 39 MAY 2016 ISSN 1366-5278 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo and Sami Hoque DOI 10.3310/hta20390 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer,1* Paul Tappenden,1 Shijie Ren,1 Marrissa Martyn-St James,1 Rebecca Harvey,1 Hasan Basarir,1 John Stevens,1 Christopher Carroll,1 Anna Cantrell,1 Alan Lobo2 and Sami Hoque3 1Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK 3Barts Health NHS Trust, London, UK *Corresponding author Declared competing interests of authors: none Published May 2016 DOI: 10.3310/hta20390 This report should be referenced as follows: Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20(39). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • Benlysta® (Belimumab)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1227-6 Program Prior Authorization/Notification Medication Benlysta® (belimumab)* *This program applies to the subcutaneous formulation of belimumab P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021 Effective Date 10/1/2021; Oxford only: 10/1/2021 1. Background: Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 2. Coverage Criteria: A. Systemic Lupus Erythematosus 1. Initial Authorization a. Benlysta will be approved based on all of the following criteria: (1) Diagnosis of systemic lupus erythematosus -AND- (2) Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB] -AND- (3) Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate] -AND- (4) Patient does not have severe active central nervous system lupus -AND- (5) Patient is not receiving Benlysta in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)] © 2021 UnitedHealthcare Services, Inc. 1 (b) Lupkynis (voclosporin) Authorization will be issued for 12 months.
    [Show full text]
  • Cutaneous Adverse Effects of Biologic Medications
    REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
    [Show full text]
  • Biologics in the Treatment of Lupus Erythematosus: a Critical Literature Review
    Hindawi BioMed Research International Volume 2019, Article ID 8142368, 17 pages https://doi.org/10.1155/2019/8142368 Review Article Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review Dominik Samotij and Adam Reich Department of Dermatology, University of Rzeszow, ul. Fryderyka Szopena 2, 35-055 Rzeszow, Poland Correspondence should be addressed to Adam Reich; adi [email protected] Received 7 May 2019; Accepted 18 June 2019; Published 18 July 2019 Academic Editor: Nobuo Kanazawa Copyright © 2019 Dominik Samotij and Adam Reich. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic lupus erythematosus (SLE) is a chronic autoimmune infammatory disease afecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventional immunosuppressive drugs, have improved life expectancy of SLE suferers. Unfortunately, in many cases efective management of SLE is still related to severe drug-induced toxicity and contributes to organ function deterioration and infective complications, particularly among patients with refractory disease and/or lupus nephritis. Consequently, there is an unmet need for drugs with a better efcacy and safety profle. A range of diferent biologic agents have been proposed and subjected to clinical trials, particularly dedicated to this subset of patients whose disease is inadequately controlled by conventional treatment regimes. Unfortunately, most of these trials have given unsatisfactory results, with belimumab being the only targeted therapy approved for the treatment of SLE so far.
    [Show full text]
  • Heart Failure and Drug-Induced Lupus
    Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush John J. Cush, MD, Chief, Rheumatology ABSTRACT demyelinating disease, cytopenias, auto- and Clinical Immunology, Presbyterian Serious and unexpected adverse events, immune disorders, and heart failure. Hospital of Dallas, Clinical Professor of such as heart failure and drug-induced Other essays in this volume address the Internal Medicine, The University of Texas lupus, have been reported in patients subject of infection (10), demyelination Southwestern Medical School, Dallas, Texas, USA. receiving TNF inhibitor therapy. These (11), and lymphoma (12). This review events generally are easily recogniz- will focus on heart failure and lupus- Please address correspondence to: John J. Cush, MD, Presbyterian Hospital able, although they cannot be predicted like disease, which are rarely seen in of Dallas, 8200 Walnut Hill Lane, Dallas, nor avoided, other than by drug avoid- association with TNF inhibitor therapy Texax 75231-4496, USA. ance altogether. Many patients have and are currently without explanation. Clin Exp Rheumatol 2004; 22 (Suppl. 35): great benefit from anti-TNF therapies. S141-S147. Their intelligent use requires a firm Sources of data © Copyright CLINICAL AND EXPERIMENTAL understanding of these rare toxicities, As a consequence of drug approval, RHEUMATOLOGY 2004. so as to minimize the morbidity associ- manufacturers have a responsibility to ated with their uncommon occurrence. collect safety data actively and report Key words: TNF inhibitors, conges- these data to the appropriate agencies. tive heart failure, drug-induced lupus, Introduction For example, in the USA a manufactur- rheumatoid arthritis. The introduction of biologic agents to er must submit periodic safety reports specifically inhibit the pro-inflammato- to the FDA twice yearly (March and ry cytokine, tumor necrosis factor (TNF), September).
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH PrXELJANZ® tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate) PrXELJANZ® XR tofacitinib extended-release, tablets, oral 11 mg tofacitinib (as tofacitinib citrate) ATC Code: L04AA29 Selective Immunosuppressant Pfizer Canada ULC Date of Preparation: 17,300 Trans-Canada Highway October 24, 2019 Kirkland, Quebec H9J 2M5 TMPF PRISM C.V. c/o Pfizer Manufacturing Holdings LLC Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2019 Submission Control No: 230976 XELJANZ/XELJANZ XR Page 1 of 80 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 ADVERSE REACTIONS..................................................................................................15 DRUG INTERACTIONS ..................................................................................................29 DOSAGE AND ADMINISTRATION..............................................................................34 OVERDOSAGE ................................................................................................................38 ACTION AND CLINICAL PHARMACOLOGY ............................................................38
    [Show full text]
  • Monoclonal Antibodies — a Revolutionary Therapy in Multiple Sclerosis
    REVIEW ARTICLE Neurologia i Neurochirurgia Polska Polish Journal of Neurology and Neurosurgery 2020, Volume 54, no. 1, pages: 21–27 DOI: 10.5603/PJNNS.a2020.0008 Copyright © 2020 Polish Neurological Society ISSN 0028–3843 Monoclonal antibodies — a revolutionary therapy in multiple sclerosis Carmen Adella Sirbu1, 2, Magdalena Budisteanu1,3,4, Cristian Falup-Pecurariu5,6 1Titu Maiorescu University, Bucharest, Romania 2‘Dr. Carol Davila’ Central Military Emergency University Hospital, Clinic of Neurology, Bucharest, Romania 3‘Prof. Dr. Alex Obregia’ Clinical Hospital of Psychiatry, Psychiatry Research Laboratory, Bucharest, Romania 4‘Victor Babes’ National Institute of Pathology, Bucharest, Romania 5Faculty of Medicine, Transylvania University of Brașov, Brașov, Romania 6Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania ABSTRACT Introduction. Multiple sclerosis (MS) has an increasing incidence and affects a young segment of the population, having a major impact on patients and consequently on society. The multifactorial aetiology and pathogenesis of this disease are incompletely known at present, but autoimmune aggression has a documented mechanism. State of the art. Since the 1990s, immunomodulatory drugs of high efficacy and a good safety profile have been launched. But the concept of NEDA (No Evidence of Disease Activity) remains the target to achieve. Thus, the new revolutionary class of monoclonal antibodies (moAbs) used in multiple medical fields, from this perspective represents a challenge even for multiple sclerosis, including the primary progressive form, for which there has been no treatment until recently. Clinical implications. In this article, we will review monoclonal antibodies’ use for MS, presenting their advantages and di- sadvantages, based on data accumulated since 2004 when the first monoclonal antibody was approved for active forms of the disease.
    [Show full text]